Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: LA Clinical Trials Clear all
Completed Not applicable Interventional

A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS

NCT00002257
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Berkeley, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Not applicable Interventional

A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus

NCT00002095
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Berkeley, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 2 Interventional

An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492

NCT00002265
View directory record Official record
Conditions
HIV Infections
Interventions
Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
San Francisco, California • Fort Lauderdale, Florida • Fort Myers, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

E-cigarette Nicotine Pharmacokinetic Study

NCT03178981
View directory record Official record
Conditions
Healthy Volunteers, Smoking
Interventions
Use electronic cigarette or smoke conventional cigarette
Other
Lead sponsor
British American Tobacco (Investments) Limited
Industry
Eligibility
22 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 1 Interventional

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

NCT00002383
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Sherman Oaks, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Short-term Safety and Use Patterns of an Electronic Nicotine Delivery System

NCT01898169
View directory record Official record
Conditions
Nicotine Dependence
Interventions
NJOY King 26 mg nicotine Electronic Nicotine Delivery System
Other
Lead sponsor
LA Clinical Trials
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study Comparing Nicotine Delivery From E-cigarettes and a Conventional Cigarette in Healthy Subjects

NCT02474849
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Use electronic cigarette or smoke conventional cigarette
Other
Lead sponsor
British American Tobacco (Investments) Limited
Industry
Eligibility
21 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 3 Interventional

A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment

NCT00002334
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Zidovudine, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

NCT00002299
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Interferon beta-1b, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 2 Interventional

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

NCT00002162
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Not applicable Interventional

Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease

NCT00002081
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wellesley Hills, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 3 Interventional

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

NCT00008528
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 4 Interventional

Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients

NCT00002229
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
20
States / cities
Hobson City, Alabama • Phoenix, Arizona • Paramount, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Not applicable Interventional

An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

NCT00002135
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Not applicable Interventional

A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir

NCT00002251
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Not applicable Interventional

A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)

NCT00002279
View directory record Official record
Conditions
HIV Infections
Interventions
Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Not applicable Interventional

A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

NCT00002222
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Valganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 4 Interventional

The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs

NCT00002425
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Not applicable Interventional

Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections

NCT00002024
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 3 Interventional

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

NCT00002378
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
97
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

NCT00002382
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 3 Interventional

A Study to Compare Two Anti-HIV Drug Combinations

NCT00002447
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Efavirenz, Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
22
States / cities
Birmingham, Alabama • Long Beach, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 1 Interventional

A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

NCT00002096
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Zidovudine, Didanosine, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Irvine, California • Washington D.C., District of Columbia • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT
Completed Phase 3 Interventional

A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients

NCT00002448
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Efavirenz, Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 6:26 PM EDT